The snakebite epidemic in India claims the lives of tens of thousands each year, highlighting a dire public health crisis that demands urgent attention.
Just recently, a poignant story emerged from Devendra, a farmer who vividly recalls the traumatic moment when a snake bit his leg while he was gathering mulberry leaves. "I didn’t seek medical help until four days after the incident, when the agony became unbearable. Unfortunately, that delay resulted in the loss of my leg," he shared in a compelling short film produced by the Global Snakebite Taskforce (GST). This initiative aims to mitigate the fatalities and injuries caused by snakebites, emphasizing the need for swift action and improved healthcare responses.
Devendra's experience, however, places him among the fortunate few who survived such a harrowing ordeal. Alarmingly, the Indian government reports that around 50,000 people fall victim to snakebites annually, accounting for approximately half of the global total. Some estimates paint an even grimmer picture, suggesting that between the years 2000 and 2019, India may have experienced up to 1.2 million fatalities related to snakebites—averaging 58,000 deaths per year based on a study conducted in 2020.
A recent report by GST has revealed that an astonishing 99% of healthcare workers in India encounter significant hurdles when it comes to administering antivenom, the crucial treatment that neutralizes the deadly toxins found in snake venom. In a comprehensive survey involving 904 medical professionals across countries severely impacted by snakebites—including India, Brazil, Indonesia, and Nigeria—researchers identified common barriers: inadequate infrastructure, limited access to antivenom supplies, and insufficient training for healthcare providers.
Almost half of those surveyed reported instances where delays in treatment resulted in severe complications for patients, including amputations and permanent mobility challenges. The report also underscores a troubling trend: snakebites disproportionately affect impoverished rural communities in low- to middle-income nations, where access to timely medical care is often severely restricted.
Dr. Yogesh Jain, a member of GST and a healthcare practitioner based in the central Chhattisgarh state, points out that a high incidence of snakebite fatalities and injuries occurs in India's central and eastern regions. He notes that individuals working in agriculture, particularly those from economically disadvantaged tribal communities, are especially vulnerable to snake encounters.
In response to this alarming situation, India unveiled the National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE) in 2024, with the ambitious goal of reducing snakebite fatalities by half by 2030. This strategic plan emphasizes the need for enhanced surveillance, improved availability of antivenom, better medical resources, and widespread public education campaigns.
While experts agree that this initiative represents a positive step forward, they caution that actual implementation has been inconsistent across various regions. "In India, snakebites are often perceived merely as a problem affecting the poor," Dr. Jain explains. "This perception contributes to the lack of sufficient outrage or proactive measures against these preventable deaths. When it comes to treating snakebites, every second is critical."
He elaborates on the urgency of the situation, noting that snake venom can enter the bloodstream within minutes, leading to severe health consequences depending on the species involved. Delays in administering antivenom can result in life-threatening conditions, including respiratory failure, paralysis, irreversible tissue damage, or even organ failure.
In rural areas of India, such delays in reaching healthcare facilities are unfortunately common. Poor transportation infrastructure, remote hospitals, and a shortage of ambulance services often hinder timely medical interventions. A heartbreaking incident last September highlighted this issue when a pregnant woman in Gujarat tragically died on her way to the hospital; her family had to carry her for five kilometers in a cloth sling due to impassable roads.
While some states are making efforts to improve access to antivenom by stocking it in primary and community health centers, the correct administration of the treatment remains a formidable challenge. Many healthcare workers lack proper training and may hesitate to administer antivenom due to the potential for adverse reactions in patients.
"Antivenom needs to be diluted with saline and administered intravenously over the course of an hour, but many facilities are ill-equipped to manage any side effects that arise," Dr. Jain mentions. Another significant challenge is the reliance of many rural inhabitants on traditional faith healers or local remedies, often delaying their visit to hospitals until symptoms become critical.
Gerry Martin, co-founder of The Liana Trust—a group dedicated to reducing human-snake conflicts in Karnataka—points out another pressing issue: the limited availability of high-quality antivenom. Currently, Indian antivenom only targets the "big four" snakes—the spectacled cobra, common krait, Russell's viper, and saw-scaled viper—which are responsible for most bites. This antivenom is typically derived from injecting venom into horses, which subsequently produce antibodies used in human treatment.
However, numerous other venomous snake species exist in India for which effective antivenom is not available. These include the green pit viper commonly found in Himachal Pradesh, various pit vipers in southern states, and many others in the northeastern regions. A study conducted by the All India Institute of Medical Sciences in Jodhpur last year underscored this problem, revealing that two-thirds of patients treated for bites by saw-scaled vipers did not respond favorably to the existing antivenom when their specific snake species was unidentified. The findings prompted calls for the development of region-specific antivenoms in western India.
For the last five years, The Liana Trust has focused on researching snake venoms beyond the big four to formulate appropriate antidotes. However, Martin notes that progress has been slow, largely due to the labor-intensive and lengthy nature of the research process. He advocates for other states to follow Karnataka's lead, which recently mandated that snakebites be classified as a "notifiable disease," thereby requiring healthcare professionals to report incidents to authorities to combat the issue of underreporting.
Dr. Jain concurs, stating, "The fight against snakebite deaths often falters where political commitment ends. Governments must ensure that impoverished populations receive adequate healthcare systems—they deserve nothing less."
But here's where it gets controversial: why does society seem to overlook such a critical issue affecting the vulnerable? What can be done to shift perceptions and prioritize action in combating this tragic reality? We invite your thoughts and opinions in the comments below.
